摘要:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.
摘要:
Various embodiments disclosed relate to conjugated polyelectrolytes and methods of using the same. Various embodiments provide a conjugated polyelectrolyte including a subunit having the structure —R1—Y—R2—Z—. At each occurrence, R1 is independently chosen from 1,4-bonded phenylene substituted by —X—R3—R4 j times and 2,5-bonded thiophene substituted by —X—R3—R4 j times. At each occurrence, Y is independently chosen from a bond and —C≡C—. At each occurrence, R2 is independently chosen from a bond, a substituted or unsubstituted phenylene, thiophenylene, azulenylene, heptalenylene, biphenylene, indacenylene, fluorenylene, phenanthrenylene, triphenylenylene, pyrenylene, naphthacenylene, chrysenylene, biphenylenylene, anthracenylene, and naphthylene. At each occurrence, Z is independently chosen from a bond and —C≡C—. The variables j, R3, and R4 are as defined herein.
摘要:
Disclosed are oxime ester compounds which have specific benzo (unsaturated 5-membered ring)-carbonyl group and their use as photoinitiators in photopolymerizable compositions, in particular in photoresist formulations for display applications, e.g. liquid crystal display (LCD), organic light emitting diode (OLED) and touch panel.
摘要:
Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.
摘要:
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
摘要:
An object is to provide a crystal having a new crystal habit of luliconazole and expand the possibility of application to pharmaceuticals. Disclosed is a crystal of luliconazole having such a crystal habit that (020) plane is a specific crystal growth surface.
摘要:
The present invention relates to piperazinyl derivatives of formula (I) and the use thereof as a drug, particularly for the treatment of cancer, the pharmaceutical compositions containing said derivatives, and the method for synthesising same.
摘要:
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
摘要:
The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
摘要:
In order to produce an intermediate from which a cyclic alcohol compound can be stereoselectively obtained, a method for producing an oxetane compound according to the present invention includes the step of reacting, with a cyanide salt, a compound represented by Formula (I): wherein R1 is selected from a hydrogen atom and an alkyl group optionally having a substituent; X1 is selected from a halogen atom and —OSO2R3 where R3 is selected from an alkyl group optionally having a substituent, a phenyl group, and a naphthyl group; and a ring Z1 represents a cyclic hydrocarbon optionally having a substituent, to obtain a compound represented by Formula (II):
摘要翻译:为了制备可以立体选择性地获得环状醇化合物的中间体,根据本发明的氧杂环丁烷化合物的制备方法包括使氰化物盐与式(I)表示的化合物反应的步骤:其中 R1选自氢原子和任选具有取代基的烷基; X1选自卤素原子和-OSO 2 R 3,其中R 3选自任选具有取代基的烷基,苯基和萘基; 并且环Z1表示任选具有取代基的环状烃,以获得由式(II)表示的化合物: